SpectraCure AB (publ) OMXSTO:SPEC:
STUDY SHOWS SIGNIFICANT PSA REDUCTION IN PROSTATE CANCER PATIENTS
PSA LEVELS DROP TO 0.0-0.5 NG/ML AFTER TREATMENT
Spectracure Says Study Shows Significant PSA Reduction In Prostate Cancer Patients
Earlier from Spectracure Ab
- Spectracure Signs Agreement With Cheplapharm For Verteporfin Supply
- Spectracure Q-Pro Patent Approved In Japan
- Spectracure Gets Approval To Commence Clinical Trial
- Spectracure Appoints Johannes Swartling As CEO